Compound isolated from Cannabis sativa extract.
The plant genus in the Cannabaceae plant family, Urticales order, Hamamelidae subclass. The flowering tops are called many slang terms including pot, marijuana, hashish, bhang, and ganja. The stem is an important source of hemp fiber.
A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.
A physiologically inactive constituent of Cannabis sativa L.
Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL.
Drugs that bind to but do not activate SEROTONIN 5-HT1 RECEPTORS, thereby blocking the actions of SEROTONIN 5-HT1 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more of the specific 5-HT1 receptor subtypes.
A subclass of cannabinoid receptor found primarily on immune cells where it may play a role modulating release of CYTOKINES.
Bornanes are a class of bicyclic organic compounds, specifically sesquiterpenes, that contain a bornane skeleton, consisting of a cyclohexane ring fused to a cyclopentane ring, and can be found in various essential oils and plants.
A class of G-protein-coupled receptors that are specific for CANNABINOIDS such as those derived from CANNABIS. They also bind a structurally distinct class of endogenous factors referred to as ENDOCANNABINOIDS. The receptor class may play a role in modulating the release of signaling molecules such as NEUROTRANSMITTERS and CYTOKINES.
Resorcinols are aromatic organic compounds containing two hydroxyl groups attached to a benzene ring, known for their antiseptic and antibacterial properties, used in various medical and cosmetic applications.
A subclass of cannabinoid receptor found primarily on central and peripheral NEURONS where it may play a role modulating NEUROTRANSMITTER release.
Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS.
Compounds that inhibit or block the activity of CANNABINOID RECEPTORS.
Endogenous compounds and drugs that specifically stimulate SEROTONIN 5-HT1 RECEPTORS. Included under this heading are agonists for one or more of the specific 5-HT1 receptor subtypes.
A serotonin receptor subtype found distributed through the CENTRAL NERVOUS SYSTEM where they are involved in neuroendocrine regulation of ACTH secretion. The fact that this serotonin receptor subtype is particularly sensitive to SEROTONIN RECEPTOR AGONISTS such as BUSPIRONE suggests its role in the modulation of ANXIETY and DEPRESSION.
Stereotyped patterns of response, characteristic of a given species, that have been phylogenetically adapted to a specific type of situation.
Amides composed of unsaturated aliphatic FATTY ACIDS linked with AMINES by an amide bond. They are most prominent in ASTERACEAE; PIPERACEAE; and RUTACEAE; and also found in ARISTOLOCHIACEAE; BRASSICACEAE; CONVOLVULACEAE; EUPHORBIACEAE; MENISPERMACEAE; POACEAE; and SOLANACEAE. They are recognized by their pungent taste and for causing numbing and salivation.
Viscous, nauseating oil obtained from the shrub Croton tiglium (Euphorbaceae). It is a vesicant and skin irritant used as pharmacologic standard for skin inflammation and allergy and causes skin cancer. It was formerly used as an emetic and cathartic with frequent mortality.
Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.

Are cannabinoids detected in hair after washing with Cannabio shampoo? (1/171)

Today, cannabis plants are used in shampoo preparations, in foodstuffs (e.g., oils, noodles, crackers, etc.), and in beverages (e.g., tea). These products often contain < 1% delta9-tetrahydrocannabinol (THC) in order to eliminate psychoactive effects, but some of them can include 1 to 3% of THC. Gas chromatography-mass spectrometry (GC-MS) analysis of Cannabio shampoo revealed the presence of THC (412 ng/mL) and two constituents of cannabis plants, cannabidiol (CBD, 4079 ng/mL) and cannabinol (CBN, 380 ng/mL). In order to verify if normal hygiene practices with Cannabio shampoo can result in positive tests for cannabinoids in hair, three subjects washed their hair with this shampoo once daily for two weeks. After this period, hair specimens were collected. In the three hair specimens, THC, CBD, and CBN were never detected within their limits of detection, 0.05, 0.02, and 0.01 ng/mg, respectively. We concluded that the use of Cannabio shampoo during normal hygiene practices cannot be considered as a source of potential contamination of hair. In a second experiment, drug-free hair specimens (200 mg) were incubated in 10 mL water/Cannabio shampoo (20:1, v/v) for 30 min, 2 h, and 5 h. After incubation, hair strands were washed with water and separated into two portions. One portion was extracted directly; the second was decontaminated with methylene chloride and then extracted. After an incubation period of 30 min, the analysis of hair by GC-MS did not reveal the presence of THC, CBD, and CBN in hair, regardless of whether the hair was decontaminated. After an incubation period of 2 h, specimens tested positive for CBD (0.11 ng/mg without decontamination and 0.10 ng/mg with decontamination) and CBN (0.02 ng/mg without decontamination and 0.02 ng/mg after decontamination). After an incubation period of 5 h, specimens tested positive for CBD (0.25 ng/mg without decontamination and 0.14 ng/mg after decontamination) and CBN (0.02 ng/mg without decontamination and 0.02 ng/mg after decontamination). In all cases, THC was never detected. Extensive but unrealistic use of Cannabio shampoo can cause drug-free hair to test positive for CBD and CBN but not for the primary psychoactive drug THC.  (+info)

Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. (2/171)

Cannabinoids, including the endogenous ligand arachidonyl ethanolamide (anandamide), elicit not only neurobehavioral but also cardiovascular effects. Two cannabinoid receptors, CB1 and CB2, have been cloned, and studies with the selective CB1 receptor antagonist SR141716A have implicated peripherally located CB1 receptors in the hypotensive action of cannabinoids. In rat mesenteric arteries, anandamide-induced vasodilation is inhibited by SR141716A, but other potent CB1 receptor agonists, such as HU-210, do not cause vasodilation, which implicates an as-yet-unidentified receptor in this effect. Here we show that "abnormal cannabidiol" (Abn-cbd) is a neurobehaviorally inactive cannabinoid that does not bind to CB1 receptors, yet causes SR141716A-sensitive hypotension and mesenteric vasodilation in wild-type mice and in mice lacking CB1 receptors or both CB1 and CB2 receptors. Hypotension by Abn-cbd is also inhibited by cannabidiol (20 microgram/g), which does not influence anandamide- or HU-210-induced hypotension. In the rat mesenteric arterial bed, Abn-cbd-induced vasodilation is unaffected by blockade of endothelial NO synthase, cyclooxygenase, or capsaicin receptors, but it is abolished by endothelial denudation. Mesenteric vasodilation by Abn-cbd, but not by acetylcholine, sodium nitroprusside, or capsaicine, is blocked by SR141716A (1 microM) or by cannabidiol (10 microM). Abn-cbd-induced vasodilation is also blocked in the presence of charybdotoxin (100 nM) plus apamin (100 nM), a combination of K(+)-channel toxins reported to block the release of an endothelium-derived hyperpolarizing factor (EDHF). These findings suggest that Abn-cbd and cannabidiol are a selective agonist and antagonist, respectively, of an as-yet-unidentified endothelial receptor for anandamide, activation of which elicits NO-independent mesenteric vasodilation, possibly by means of the release of EDHF.  (+info)

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. (3/171)

The therapeutic potential of cannabidiol (CBD), the major nonpsychoactive component of cannabis, was explored in murine collagen-induced arthritis (CIA). CIA was elicited by immunizing DBA/1 mice with type II collagen (CII) in complete Freund's adjuvant. The CII used was either bovine or murine, resulting in classical acute CIA or in chronic relapsing CIA, respectively. CBD was administered after onset of clinical symptoms, and in both models of arthritis the treatment effectively blocked progression of arthritis. CBD was equally effective when administered i.p. or orally. The dose dependency showed a bell-shaped curve, with an optimal effect at 5 mg/kg per day i.p. or 25 mg/kg per day orally. Clinical improvement was associated with protection of the joints against severe damage. Ex vivo, draining lymph node cells from CBD-treated mice showed a diminished CII-specific proliferation and IFN-gamma production, as well as a decreased release of tumor necrosis factor by knee synovial cells. In vitro effects of CBD included a dose-dependent suppression of lymphocyte proliferation, both mitogen-stimulated and antigen-specific, and the blockade of the Zymosan-triggered reactive oxygen burst by peritoneal granulocytes. It also was found that CBD administration was capable of blocking the lipopolysaccharide-induced rise in serum tumor necrosis factor in C57/BL mice. Taken together, these data show that CBD, through its combined immunosuppressive and anti-inflammatory actions, has a potent anti-arthritic effect in CIA.  (+info)

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. (4/171)

1. (-)-Cannabidiol (CBD) is a non-psychotropic component of Cannabis with possible therapeutic use as an anti-inflammatory drug. Little is known on the possible molecular targets of this compound. We investigated whether CBD and some of its derivatives interact with vanilloid receptor type 1 (VR1), the receptor for capsaicin, or with proteins that inactivate the endogenous cannabinoid, anandamide (AEA). 2. CBD and its enantiomer, (+)-CBD, together with seven analogues, obtained by exchanging the C-7 methyl group of CBD with a hydroxy-methyl or a carboxyl function and/or the C-5' pentyl group with a di-methyl-heptyl (DMH) group, were tested on: (a) VR1-mediated increase in cytosolic Ca(2+) concentrations in cells over-expressing human VR1; (b) [(14)C]-AEA uptake by RBL-2H3 cells, which is facilitated by a selective membrane transporter; and (c) [(14)C]-AEA hydrolysis by rat brain membranes, which is catalysed by the fatty acid amide hydrolase. 3. Both CBD and (+)-CBD, but not the other analogues, stimulated VR1 with EC(50)=3.2 - 3.5 microM, and with a maximal effect similar in efficacy to that of capsaicin, i.e. 67 - 70% of the effect obtained with ionomycin (4 microM). CBD (10 microM) desensitized VR1 to the action of capsaicin. The effects of maximal doses of the two compounds were not additive. 4. (+)-5'-DMH-CBD and (+)-7-hydroxy-5'-DMH-CBD inhibited [(14)C]-AEA uptake (IC(50)=10.0 and 7.0 microM); the (-)-enantiomers were slightly less active (IC(50)=14.0 and 12.5 microM). 5. CBD and (+)-CBD were also active (IC(50)=22.0 and 17.0 microM). CBD (IC(50)=27.5 microM), (+)-CBD (IC(50)=63.5 microM) and (-)-7-hydroxy-CBD (IC(50)=34 microM), but not the other analogues (IC(50)>100 microM), weakly inhibited [(14)C]-AEA hydrolysis. 6. Only the (+)-isomers exhibited high affinity for CB(1) and/or CB(2) cannabinoid receptors. 7. These findings suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues. In view of the facile high yield synthesis, and the weak affinity for CB(1) and CB(2) receptors, (-)-5'-DMH-CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent.  (+info)

The inhibition of DNA synthesis by cannabinoids. (5/171)

Several of the cannabinoids found in marihuana have been shown to inhibit tumor growth and increase the life-span of mice bearing the Lewis lung adenocarcinoma. When trypsin-dispersed isolated Lewis lung cells are incubated in vitro, they maintain their capacity to carry out macromolecular synthesis (RNA, DNA, protein). This process can be inhibited by cytosine arabinoside, actinomycin D, or methyl-1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, whereas cyclophosphamide, an agent that must be bioactivated, was inactive. Inhibition of DNA synthesis as measured by [3H]thymidine uptake into acid-insoluble material was used as an index of cannabinoid activity against isolated Lewis lung cells, L1210 leukemia cells, and bone marrow cells incubated in vitro delta9-, delta8-, 1-hydroxy-3-n pentyl-, and 1-delta8-tetrahydrocannabinol, and cannabinol demonstrated a dose-dependent inhibition of DNA synthesis whereas cannabidiol and 1-hydroxy-3-n-pentylcannabidiol were markedly less inhibitory in our in vitro cell systems. Furthermore, our in vitro observations with these cannabinoids are supported by in vivo tumor inhibition studies. Ring modifications as in cannabichromene or cannabicyclol abolish in vitro activity as does dihydroxylation at the 8beta and 11 positions of 1-delta9-trans-tetrahydrocannabinol. Delta9-trans-tetrahydrocannabinol demonstrated the least toxicity of all inhibitory cannabinoids in vivo; this is supported by its lesser effect on bone marrow DNA synthesis in vitro.  (+info)

The inheritance of chemical phenotype in Cannabis sativa L. (6/171)

Four crosses were made between inbred Cannabis sativa plants with pure cannabidiol (CBD) and pure Delta-9-tetrahydrocannabinol (THC) chemotypes. All the plants belonging to the F(1)'s were analyzed by gas chromatography for cannabinoid composition and constantly found to have a mixed CBD-THC chemotype. Ten individual F(1) plants were self-fertilized, and 10 inbred F(2) offspring were collected and analyzed. In all cases, a segregation of the three chemotypes (pure CBD, mixed CBD-THC, and pure THC) fitting a 1:2:1 proportion was observed. The CBD/THC ratio was found to be significantly progeny specific and transmitted from each F(1) to the F(2)'s derived from it. A model involving one locus, B, with two alleles, B(D) and B(T), is proposed, with the two alleles being codominant. The mixed chemotypes are interpreted as due to the genotype B(D)/B(T) at the B locus, while the pure-chemotype plants are due to homozygosity at the B locus (either B(D)/B(D) or B(T)/B(T)). It is suggested that such codominance is due to the codification by the two alleles for different isoforms of the same synthase, having different specificity for the conversion of the common precursor cannabigerol into CBD or THC, respectively. The F(2) segregating groups were used in a bulk segregant analysis of the pooled DNAs for screening RAPD primers; three chemotype-associated markers are described, one of which has been transformed in a sequence-characterized amplified region (SCAR) marker and shows tight linkage to the chemotype and codominance.  (+info)

Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. (7/171)

The cannabinoid analog abnormal cannabidiol [abn-cbd; (-)-4-(3-3,4-trans-p-menthadien-[1,8]-yl)-olivetol] does not bind to CB(1) or CB(2) receptors, yet it acts as a full agonist in relaxing rat isolated mesenteric artery segments. Vasorelaxation by abn-cbd is endothelium-dependent, pertussis toxin-sensitive, and is inhibited by the BK(Ca) channel inhibitor charybdotoxin, but not by the nitric-oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester or by the vanilloid VR1 receptor antagonist capsazepine. The cannabidiol analog O-1918 does not bind to CB(1) or CB(2) receptors and does not cause vasorelaxation at concentrations up to 30 microM, but it does cause concentration-dependent (1-30 microM) inhibition of the vasorelaxant effects of abn-cbd and anandamide. In anesthetized mice, O-1918 dose-dependently inhibits the hypotensive effect of abn-cbd but not the hypotensive effect of the CB(1) receptor agonist (-)-11-OH-Delta(9)-tetrahydrocannabinol dimethylheptyl. In human umbilical vein endothelial cells, abn-cbd induces phosphorylation of p42/44 mitogen-activated protein kinase and protein kinase B/Akt, which is inhibited by O-1918, by pertussis toxin or by phosphatidylinositol 3 (PI3) kinase inhibitors. These findings indicate that abn-cbd is a selective agonist and that O-1918 is a selective, silent antagonist of an endothelial "anandamide receptor", which is distinct from CB(1) or CB(2) receptors and is coupled through G(i)/G(o) to the PI3 kinase/Akt signaling pathway.  (+info)

Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. (8/171)

1. The nonpsychoactive cannabinoid abnormal-cannabidiol (trans-4-[3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenedio l) (abn-cbd) produced concentration-dependent relaxation of methoxamine-precontracted rat small mesenteric artery. Endothelial removal reduced abn-cbd potency six-fold without affecting the maximum relaxation. 2. In endothelium-intact vessels, abn-cbd was less potent under 60 mM KCl-induced tone and inhibited by combination of L-N(G)-nitroarginine methyl ester (L-NAME) (nitric oxide synthase inhibitor; 300 micro M), apamin (small conductance Ca(2+)-activated K(+) channels inhibitor; 50 nM) and charybdotoxin (inhibitor of intermediate conductance Ca(2+)-activated K(+) channels and large conductance Ca(2+)-activated K(+) channels BK(Ca); 50 nM). L-NAME alone or in combination with either toxin alone had little effect. 3. In intact vessels, relaxations to abn-cbd were inhibited by SR 141716A (cannabinoid receptor antagonist; 1 or 3 micro M). Concomitant addition of L-NAME, apamin and charybdotoxin had no further effect. Other cannabinoid receptor antagonists either had little (SR 144528; 1 micro M and AM 251; 1 micro M) or no effect (AM 630; 10 micro M and AM 281; 1 micro M). Inhibition of gap junctions, G(i/o) protein coupling and protein kinase A also had no effect. 4. Endothelium-independent relaxation to abn-cbd was unaffected by L-NAME, apamin plus charybdotoxin or capsaicin (10 micro M). Abn-cbd inhibited CaCl(2)-induced contractions in vessels with depleted intracellular Ca(2+) stores and stimulated with methoxamine or KCl. This was insensitive to SR 141716A (3 micro M) but greatly reduced in vessels stimulated with ionomycin (Ca(2+) ionophore; 1 micro M). 5. We conclude that abn-cbd relaxes the rat small mesenteric artery by endothelium-dependent activation of K(+) channels via SR 141716A-sensitive pathways, which do not involve CB(1) and CB(2) receptors. It also causes endothelium-independent, SR 141716A-insensitive, relaxation by inhibiting Ca(2+) entry through voltage-gated Ca(2+) channels.  (+info)

Cannabidiol (CBD) is a chemical compound found in the Cannabis sativa plant, also known as cannabis or marijuana. It is one of many such compounds, known as cannabinoids, that are found in the plant. Unlike tetrahydrocannabinol (THC), which is the main psychoactive component of cannabis and is responsible for the "high" associated with its use, CBD does not have psychoactive effects.

CBD has been studied for its potential therapeutic uses in a variety of medical conditions, including epilepsy, anxiety, and chronic pain. It is available in various forms, such as oils, capsules, and topical creams, and can be taken orally or applied to the skin. However, it is important to note that the use of CBD is not currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of any medical condition, except for the treatment of certain forms of epilepsy. As with any medication or supplement, it is important to talk to your doctor before using CBD, especially if you are taking other medications or have underlying health conditions.

Cannabis is a plant genus that includes three species: Cannabis sativa, Cannabis indica, and Cannabis ruderalis. It contains psychoactive compounds called cannabinoids, the most notable of which is delta-9-tetrahydrocannabinol (THC), which produces the "high" associated with marijuana use.

Cannabis sativa and Cannabis indica are primarily used for recreational and medicinal purposes, while Cannabis ruderalis has a lower THC content and is mainly used for industrial purposes, such as hemp fiber production.

Medicinally, cannabis is used to treat various conditions, including pain, nausea, and loss of appetite associated with cancer and HIV/AIDS, multiple sclerosis, epilepsy, and post-traumatic stress disorder (PTSD), among others. However, its use remains controversial due to its psychoactive effects and potential for abuse. Its legal status varies widely around the world, ranging from outright prohibition to decriminalization or full legalization for medical and/or recreational purposes.

Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), which is the main psychoactive compound found in cannabis. It is approved by the US Food and Drug Administration (FDA) for the treatment of nausea and vomiting caused by chemotherapy in cancer patients, as well as to stimulate appetite and weight gain in patients with AIDS wasting syndrome.

Dronabinol is available in capsule form and is typically taken two to three times a day, depending on the prescribed dosage. It may take several days or even weeks of regular use before the full therapeutic effects are achieved.

Like cannabis, dronabinol can cause psychoactive effects such as euphoria, altered mood, and impaired cognitive function. Therefore, it is important to follow the prescribing instructions carefully and avoid driving or operating heavy machinery while taking this medication. Common side effects of dronabinol include dizziness, drowsiness, dry mouth, and difficulty with coordination.

Cannabinol (CBN) is a chemical compound found in cannabis plants. It is one of the many cannabinoids that can be extracted from the plant, but it is not as well-known or widely studied as tetrahydrocannabinol (THC) and cannabidiol (CBD).

CBN is formed when THC degrades over time due to exposure to air, heat, and light. As a result, older or improperly stored cannabis may contain higher levels of CBN than fresh or properly stored cannabis.

CBN has been shown to have some therapeutic potential, including as a sedative, an anti-inflammatory, and an appetite stimulant. However, more research is needed to fully understand its effects and potential medical uses. It's worth noting that CBN does not produce the psychoactive effects associated with THC.

Cannabinoids are a class of chemical compounds that are produced naturally in the resin of the cannabis plant (also known as marijuana). There are more than 100 different cannabinoids that have been identified, the most well-known of which are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).

THC is the primary psychoactive component of cannabis, meaning it is responsible for the "high" or euphoric feeling that people experience when they use marijuana. CBD, on the other hand, does not have psychoactive effects and is being studied for its potential therapeutic uses in a variety of medical conditions, including pain management, anxiety, and epilepsy.

Cannabinoids work by interacting with the body's endocannabinoid system, which is a complex network of receptors and chemicals that are involved in regulating various physiological processes such as mood, appetite, pain sensation, and memory. When cannabinoids bind to these receptors, they can alter or modulate these processes, leading to potential therapeutic effects.

It's important to note that while some cannabinoids have been shown to have potential medical benefits, marijuana remains a controlled substance in many countries, and its use is subject to legal restrictions. Additionally, the long-term health effects of using marijuana or other forms of cannabis are not fully understood and are the subject of ongoing research.

Serotonin 5-HT1 receptor antagonists are a class of pharmaceutical drugs that block the activation of serotonin 5-HT1 receptors. Serotonin, also known as 5-hydroxytryptamine (5-HT), is a neurotransmitter that plays a role in various physiological functions, including mood regulation, appetite control, and sensory perception. The 5-HT1 receptor family includes several subtypes (5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F) that are widely distributed throughout the central and peripheral nervous systems.

When serotonin binds to these receptors, it triggers a series of intracellular signaling events that can have excitatory or inhibitory effects on neuronal activity. By blocking the interaction between serotonin and 5-HT1 receptors, antagonists modulate the downstream consequences of receptor activation.

Serotonin 5-HT1 receptor antagonists are used in various clinical contexts to treat or manage a range of conditions:

1. Migraine prevention: Some 5-HT1B/1D receptor antagonists, such as sumatriptan and rizatriptan, are highly effective in aborting migraine attacks by constricting dilated cranial blood vessels and reducing the release of pro-inflammatory neuropeptides.
2. Nausea and vomiting: Certain 5-HT3 receptor antagonists, like ondansetron and granisetron, are used to prevent chemotherapy-induced nausea and vomiting by blocking the activation of emetic circuits in the brainstem.
3. Psychiatric disorders: Although not widely used, some 5-HT1A receptor antagonists have shown promise in treating depression and anxiety disorders due to their ability to modulate serotonergic neurotransmission.
4. Neuroprotection: Preclinical studies suggest that 5-HT1A receptor agonists may have neuroprotective effects in various neurological conditions, such as Parkinson's disease and stroke. However, further research is needed to establish their clinical utility.

In summary, serotonin 5-HT1 receptor antagonists are a diverse group of medications with applications in migraine prevention, nausea and vomiting management, psychiatric disorders, and potential neuroprotection. Their unique pharmacological profiles enable them to target specific pathophysiological mechanisms underlying various conditions, making them valuable tools in modern therapeutics.

A cannabinoid receptor CB2 is a G-protein coupled receptor that is primarily found in the immune system and cells associated with the immune system. They are expressed on the cell surface and are activated by endocannabinoids, plant-derived cannabinoids (phytocannabinoids) like those found in marijuana, and synthetic cannabinoids.

CB2 receptors are involved in a variety of physiological processes including inflammation, pain perception, and immune function. They have been shown to play a role in modulating the release of cytokines, which are signaling molecules that mediate and regulate immunity and inflammation. CB2 receptors may also be found in the brain, although at much lower levels than CB1 receptors.

CB2 receptor agonists have been studied as potential treatments for a variety of conditions including pain management, neuroinflammation, and autoimmune disorders. However, more research is needed to fully understand their therapeutic potential and any associated risks.

I'm sorry for any confusion, but "bornanes" is not a medical term or concept. It is a chemical term that refers to a class of compounds called bornane derivatives, which are structurally related to the naturally occurring compound bornane. These compounds have various uses in chemistry and materials science, but they do not have specific relevance to medicine or human health.

Cannabinoid receptors are a class of cell membrane receptors in the endocannabinoid system that are activated by cannabinoids. The two major types of cannabinoid receptors are CB1 receptors, which are predominantly found in the brain and central nervous system, and CB2 receptors, which are primarily found in the immune system and peripheral tissues. These receptors play a role in regulating various physiological processes such as appetite, pain-sensation, mood, and memory. They can be activated by endocannabinoids (cannabinoids produced naturally in the body), phytocannabinoids (found in cannabis plants), and synthetic cannabinoids.

Resorcinols are a type of chemical compound that contain a resorcinol moiety, which is made up of a benzene ring with two hydroxyl groups in the ortho position. In medicine, resorcinol and its derivatives have been used for various purposes, including as antiseptics, antibacterials, and intermediates in the synthesis of other pharmaceuticals.

Resorcinol itself has some medicinal properties, such as being able to reduce pain and inflammation, and it has been used topically to treat conditions like eczema, psoriasis, and acne. However, resorcinol can also be toxic in large amounts, so it must be used with caution.

It's important to note that while resorcinol is a chemical compound, the term "resorcinols" may also refer to a group of related compounds that contain the resorcinol moiety. These compounds can have different medicinal properties and uses depending on their specific structure and function.

A cannabinoid receptor, CB1, is a G protein-coupled receptor that is primarily found in the brain and central nervous system. It is one of the two main types of cannabinoid receptors, the other being CB2, and is activated by the endocannabinoid anandamide and the phytocannabinoid Delta-9-tetrahydrocannabinol (THC), which is the primary psychoactive component of cannabis. The activation of CB1 receptors is responsible for many of the psychological effects of cannabis, including euphoria, altered sensory perception, and memory impairment. CB1 receptors are also found in peripheral tissues, such as the adipose tissue, liver, and muscles, where they play a role in regulating energy metabolism, appetite, and pain perception.

Cannabinoid receptor agonists are compounds that bind to and activate cannabinoid receptors, which are part of the endocannabinoid system in the human body. These receptors are involved in various physiological processes, including pain modulation, appetite regulation, memory, and mood.

There are two main types of cannabinoid receptors: CB1 receptors, which are primarily found in the brain and central nervous system, and CB2 receptors, which are mainly found in the immune system and peripheral tissues.

Cannabinoid receptor agonists can be classified based on their chemical structure and origin. Some naturally occurring cannabinoids, such as THC (tetrahydrocannabinol) and CBD (cannabidiol), are found in the Cannabis sativa plant and can activate cannabinoid receptors. Synthetic cannabinoids, on the other hand, are human-made compounds designed to mimic or enhance the effects of natural cannabinoids.

Examples of cannabinoid receptor agonists include:

1. THC (tetrahydrocannabinol): The primary psychoactive component of marijuana, THC binds to CB1 receptors and produces feelings of euphoria or "high." It also has analgesic, anti-inflammatory, and appetite-stimulating properties.
2. CBD (cannabidiol): A non-psychoactive compound found in cannabis, CBD has a more complex interaction with the endocannabinoid system. While it does not bind strongly to CB1 or CB2 receptors, it can influence their activity and modulate the effects of other cannabinoids. CBD is known for its potential therapeutic benefits, including anti-inflammatory, analgesic, anxiolytic, and neuroprotective properties.
3. Synthetic cannabinoids: These are human-made compounds designed to mimic or enhance the effects of natural cannabinoids. Examples include dronabinol (Marinol), a synthetic THC used to treat nausea and vomiting in cancer patients, and nabilone (Cesamet), another synthetic THC used to manage pain and nausea in cancer and AIDS patients.
4. CP 55,940: A potent synthetic cannabinoid agonist that binds to both CB1 and CB2 receptors with high affinity. It is used in research to study the endocannabinoid system and its functions.
5. WIN 55,212-2: Another synthetic cannabinoid agonist that binds to both CB1 and CB2 receptors. It is often used in research to investigate the therapeutic potential of cannabinoids.

It's important to note that while some cannabinoid receptor agonists have demonstrated therapeutic benefits, they can also have side effects and potential risks, particularly when used in high doses or without medical supervision. Always consult a healthcare professional before using any cannabinoid-based medication or supplement.

Cannabinoid receptor antagonists are a class of compounds that bind to and block cannabinoid receptors, which are specialized proteins found on the surface of certain cells in the body. These receptors play an important role in regulating various physiological processes, including pain perception, appetite regulation, and memory formation.

There are two main types of cannabinoid receptors: CB1 receptors, which are primarily found in the brain and central nervous system, and CB2 receptors, which are mainly found in immune cells and other peripheral tissues.

Cannabinoid receptor antagonists work by preventing the activation of these receptors by natural cannabinoids such as THC (tetrahydrocannabinol), the main psychoactive component of marijuana. By blocking the effects of THC, cannabinoid receptor antagonists can be used to treat conditions that are exacerbated by THC, such as substance use disorders and psychosis.

One example of a cannabinoid receptor antagonist is rimonabant, which was approved in Europe for the treatment of obesity but was later withdrawn from the market due to concerns about psychiatric side effects. Other cannabinoid receptor antagonists are currently being investigated for their potential therapeutic uses, including the treatment of pain, inflammation, and neurodegenerative disorders.

Serotonin 5-HT1 Receptor Agonists are a class of compounds that bind to and activate the serotonin 5-HT1 receptors, which are G protein-coupled receptors found in the central and peripheral nervous systems. These receptors play important roles in regulating various physiological functions, including neurotransmission, vasoconstriction, and hormone secretion.

Serotonin 5-HT1 Receptor Agonists are used in medical therapy to treat a variety of conditions, such as migraines, cluster headaches, depression, anxiety, and insomnia. Some examples of Serotonin 5-HT1 Receptor Agonists include sumatriptan, rizatriptan, zolmitriptan, naratriptan, and frovatriptan, which are used to treat migraines and cluster headaches by selectively activating the 5-HT1B/1D receptors in cranial blood vessels and sensory nerves.

Other Serotonin 5-HT1 Receptor Agonists, such as buspirone, are used to treat anxiety disorders and depression by acting on the 5-HT1A receptors in the brain. These drugs work by increasing serotonergic neurotransmission, which helps to regulate mood, cognition, and behavior.

Overall, Serotonin 5-HT1 Receptor Agonists are a valuable class of drugs that have shown efficacy in treating various neurological and psychiatric conditions. However, like all medications, they can have side effects and potential drug interactions, so it is important to use them under the guidance of a healthcare professional.

A serotonin receptor, specifically the 5-HT1A subtype, is a type of G protein-coupled receptor found in the central and peripheral nervous systems. These receptors are activated by the neurotransmitter serotonin (5-hydroxytryptamine or 5-HT) and play important roles in regulating various physiological processes, including neurotransmission, neuronal excitability, and neuroendocrine function.

The 5-HT1A receptor is widely distributed throughout the brain and spinal cord, where it is involved in modulating mood, anxiety, cognition, memory, and pain perception. Activation of this receptor can have both inhibitory and excitatory effects on neuronal activity, depending on the location and type of neuron involved.

In addition to its role in normal physiology, the 5-HT1A receptor has been implicated in various pathological conditions, including depression, anxiety disorders, schizophrenia, and drug addiction. As a result, drugs that target this receptor have been developed for the treatment of these conditions. These drugs include selective serotonin reuptake inhibitors (SSRIs), which increase the availability of serotonin in the synaptic cleft and enhance 5-HT1A receptor activation, as well as direct agonists of the 5-HT1A receptor, such as buspirone, which is used to treat anxiety disorders.

In the context of medicine and biology, instinct is not typically used as a medical term. However, in general terms, instinct refers to a complex, adaptive behavior that is inherited and is not based on learning or reasoning. It's a genetically programmed response to certain stimuli that helps an organism survive and reproduce.

In psychology, instincts are often considered to be innate drives or motivations that underlie behavior. In this context, the term "instinct" may be used in a medical or clinical setting to describe certain behaviors or responses that are thought to have a strong biological basis and are not primarily learned or voluntary.

It's important to note that the concept of instinct is complex and can be interpreted differently across various fields of study, so any definition may depend on the context in which it is being used.

I'm sorry for any confusion, but "Polyunsaturated Alkamides" is not a widely recognized medical term or concept. It seems to be a combination of two different terms: "polyunsaturated" which relates to fatty acid chemistry, and "alkamides" which are a type of compound found in certain plants.

1. Polyunsaturated: This term refers to fatty acids that have multiple double bonds in their carbon chain. These fatty acids are essential to the human diet and are commonly found in foods like fish, nuts, and seeds. They are often referred to as Omega-3 or Omega-6 fatty acids.

2. Alkamides: These are a type of compound found in some plants, including Echinacea species. They have been studied for their potential biological activities, such as anti-inflammatory and immunomodulatory effects.

Without more context, it's difficult to provide a precise definition or medical interpretation of "Polyunsaturated Alkamides." If you have more information about how these terms are being used together, I'd be happy to try to provide a more specific answer.

Croton oil is a highly toxic, irritant, and vesicant liquid that is derived from the seeds of the croton tiglium plant. It is a type of unsaturated fatty acid known as an octadecatrienoic acid, and it contains a mixture of various chemical compounds including crotonic acid, diglycerides, and phorbol esters.

Croton oil is commonly used in laboratory research as a pharmacological tool to study the mechanisms of inflammation, pain, and skin irritation. It can also be used as a veterinary medicine to treat certain types of intestinal parasites in animals. However, due to its high toxicity and potential for causing severe burns and blisters on the skin, it is not used in human medicine.

It's important to note that croton oil should only be handled by trained professionals in a controlled laboratory setting, as improper use or exposure can result in serious injury or death.

Cyclohexanols are a class of organic compounds that contain a cyclohexane ring (a six-carbon saturated ring) with a hydroxyl group (-OH) attached to it. The hydroxyl group makes these compounds alcohols, and the cyclohexane ring provides a unique structure that can adopt different conformations.

The presence of the hydroxyl group in cyclohexanols allows them to act as solvents, intermediates in chemical synthesis, and starting materials for the production of other chemicals. They are used in various industries, including pharmaceuticals, agrochemicals, and polymers.

Cyclohexanols can exist in different forms, such as cis- and trans-isomers, depending on the orientation of the hydroxyl group relative to the cyclohexane ring. The physical and chemical properties of these isomers can differ significantly due to their distinct structures and conformations.

Examples of cyclohexanols include cyclohexanol itself (C6H11OH), as well as its derivatives, such as methylcyclohexanol (C7H13OH) and phenylcyclohexanol (C12H15OH).

Cannabidiol (CBD) is an active ingredient in cannabis that is derived from the hemp plant, but it does not cause a high and is ... How is cannabidiol different from marijuana, cannabis and hemp?. CBD, or cannabidiol, is the second most prevalent active ... Cannabidiol (CBD): What we know and what we dont September 24, 2021 By Peter Grinspoon, MD, Contributor ... Cannabidiol (CBD) is often covered in the media, and you may see it touted as an add-in booster to your post-workout smoothie ...
"Cannabidiol (CBD) guidance - Business guidance on cannabidiol (CBD) as a novel food". UK Food Standards Agency. September 24, ... Additionally, it approved Nabiximols, a cannabidiol-containing drug, for medical use. Cannabidiol, in an oral-mucosal spray ... Cannabidiol does not appear to have any intoxicating effects such as those caused by ∆9-THC in cannabis, but it is under ... Cannabidiol has low affinity for the cannabinoid CB1 and CB2 receptors, although it acts as an antagonist of CB1/CB2 agonists, ...
Cannabidiol: learn about side effects, dosage, special precautions, and more on MedlinePlus ... You may take cannabidiol either with or without food, but be sure to take it the same way each time. Take cannabidiol at around ... Cannabidiol helps to control your condition, but does not cure it. Continue to take cannabidiol even if you feel well. Do not ... Before taking cannabidiol,. *tell your doctor and pharmacist if you are allergic to cannabidiol, any other medications, sesame ...
By Flora Southey The Cannabis Trades Association has criticised the Food Standards Agencys refusal to postpone its CBD novel foods deadline, describing the move as unsympathetic to businesses in the sector. ...
Cannabidiol (CBD), a non-psychoactive compound in cannabis, is being touted as beneficial for many health conditions, ranging ... Cannabidiol could help deliver medications to the brain. Date:. April 17, 2019. Source:. American Chemical Society. Summary:. ... "Cannabidiol could help deliver medications to the brain." ScienceDaily. www.sciencedaily.com. /. releases. /. 2019. /. 04. /. ... Cannabidiol Enhances the Passage of Lipid Nanocapsules across the Blood-Brain Barrier Both in Vitro and in Vivo. Molecular ...
Patients with hand osteoarthritis or psoriatic arthritis who used cannabidiol as an add-on analgesic had results similar to ... Use of cannabidiol (CBD) as an add-on pain management technique in patients with either hand osteoarthritis (OA) or psoriatic ... Cite this: Cannabidiol Found No Better Than Placebo for Hand Arthritis Pain - Medscape - Sep 16, 2021. ...
... March 10, 2020. Courtney Skriptshak, PharmD. Jenel Clement, PharmD*Amy T. Murdico, PharmD, ... Cannabidiol (CBD) has been gaining popularity over the past few years and is now found in many pharmacies, supermarkets, and ... Cannabidiol is touted as helping with a number of different conditions, such as anxiety, pain, and seizures, and is available ... Cannabidiol is a substance isolated from the cannabis plant, which is the same plant from which tetrahydrocannabinol (THC), the ...
Learn more about Cannabidiol health benefits, uses, side effects, effectiveness, safety, precautions, and warnings ... Cannabidiol is POSSIBLY SAFE when taken by mouth or sprayed under the tongue appropriately in adults. Cannabidiol doses of up ... People inhale cannabidiol to help quit smoking.. How does it work?. Cannabidiol has antipsychotic effects. The exact cause for ... Cannabidiol might decrease how quickly the liver breaks down some medications. In theory, using cannabidiol along with some ...
Find Cannabidiol near me in Bolton, Lancashire on Yell. Get reviews and contact details for each business including phone ... Cannabidiol near me in Bolton, Lancashire Did you mean a different Bolton? ...
Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic ... 2 have caused much confusion and uncertainty whether oral cannabidiol (CBD) is safe and whether subjects who are treated with ... "A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans". The views expressed here are ...
Cannabidiol, DNA: Deoxyribonucleic acid, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HIV/AIDS: Human immunodeficiency virus ... Cannabidiol exhibited ,i,in vitro,/i, activity against viral hepatitis C. ,b,Abbreviations Used,/b,: CB2: Cannabis receptor 2, ... Potential of Cannabidiol for the Treatment of Viral Hepatitis Pharmacognosy Res. 2017 Jan-Mar;9(1):116-118. doi: 10.4103/0974- ... Summary: Cannabidiol exhibited in vitro activity against viral hepatitis C. Abbreviations Used: CB2: Cannabis receptor 2, CBD: ...
Search for Anti-Aging information and Medical News in Cannabidiol (CBD) within the Longevity and Age Management section ... Search for Anti-Aging information and Medical News in Cannabidiol (CBD) within the Longevity and Age Management section ...
Cannabidiol is known to interact with multiple epilepsy drugs and has been linked to raised liver enzymes aspartate ... More patients on cannabidiol had at least a 50% reduction in convulsive seizures compared with those on placebo. Caregivers of ... Smooth Sailing for Cannabidiol in Dravet, Lennox-Gastaut?. - FDA staff review generally favorable ahead of advisory committee ... Cannabidiol also produced greater median reduction in seizure frequency and higher overall improvement on the Subject/Caregiver ...
PRNewswire/ -- Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness ... Launches Line of Cannabidiol (CBD) Supplements as Alternative to Medical Marijuana Legal, hemp-based supplements offer ... 4, 2014 /PRNewswire/ -- Hemp Health Inc., a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD ... is a developer, retailer and wholesaler of hemp cannabidiol (CBD) supplements. The company offers CBD in capsule, raw oil and ...
Key features of the synthesised variant of trans-cannabidiol include:. *IUPAC Name: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-yl-1- ... Key features of the isolated variant of trans-cannabidiol include:. *Made from part of the leaves and infrastructure of ... CBDepots trans-cannabidiol (CBD) is available in purities of greater than 98%. ... CBDepots trans-cannabidiol (CBD) is available in purities of greater than 98%. ...
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an ... Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an ... Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an ... Here we report that cannabidiol, a major non-psychoactive cannabinoid found in marijuana and its synthetic dimethylheptyl ...
The Iowa Medical Cannabidiol Board is considering changes to the states CBD program, including the addition of more qualifying ... If the Medical Cannabidiol Board votes to approve one or more of the petitions to add qualifying conditions to the states ... Iowa Medical Cannabidiol Board To Consider Adding More Qualifying Conditions. They are also considering changes to their THC ... Home Marijuana News Iowa Iowa Medical Cannabidiol Board To Consider Adding More Qualifying Conditions ...
Cannabidiol is a Powerful New Antibiotic. June 23, 2019. San Francisco, Calif. - June 23, 2019 - New research has found that ... Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for ... Cannabidiol was also effective at disrupting biofilms, a physical form of bacteria growth that leads to difficult-to-treat ... "Given cannabidiols documented anti-inflammatory effects, existing safety data in humans, and potential for varied delivery ...
One solution has been highly touted, however: cannabidiol.. Want the latest lab management news?. Subscribe to our free Lab ... Study: Cannabidiol Ineffective in Treating Cocaine Addiction. A recently-published study by a Canadian scientific team shows ... MONTREAL, QC, CANADA - Taking cannabidiol, a chemical in the cannabis sativa plant, appears ineffective in treating cocaine use ... one receiving cannabidiol (800 mg/ per day), the other a placebo. ... cannabidiol is probably not a good choice. ...
This crystalline cannabidiol (CBD) is derived from Kentucky-grown hemp and isolated via CO2 extraction and crystal ... Ingredient Snapshot: This crystalline cannabidiol (CBD) is derived from Kentucky-grown hemp and isolated via CO2 extraction and ... Pharmaceutical & hemp wellness segments of cannabidiol market could see fastest growth. See More ...
Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of ... Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of ... The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets Int J ...
Cannabidiol (CBD) is a phytocannabinoid obtained from the hemp plant (Cannabis sativa). It comes as a 99.9% pure isolate powder ...
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience ...
Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic ... Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic ... While cannabidiol (CBD) is currently infrequently used for the treatment of juvenile idiopathic arthritis (JIA), there is a ... Growing Interest in Cannabidiol for Juvenile Idiopathic Arthritis. Dec 16, 2021. Lana Pine ...
... Facebook Twitter ... these gummies make integrating cannabidiol into your everyday life easy. The shock in CBD oil for hair CBD oil in bend Oregon ...
... Facebook Twitter ... Tama Fetzer shouted The concubine is cannabidiol CBD gummies old slave really didnt do any evil Elroy Haslett CBD gummies ...
Lacking any central effect, cannabidiol is an attract ... Cannabidiol (CBD) is an anti-inflammatory cannabinoid shown to ... Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem. 2015;23:1377-1385. ... Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol. 2008;154: ... Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohns Disease, a Randomized Controlled Trial. *Timna ...
  • Cannabidiol (CBD), a major cannabinoid of hemp, does not bind to CB1 receptors and is therefore devoid of psychotomimetic properties. (genengnews.com)
  • Cannabidiol, a cannabinoid prepared from marijuana, is structurally unrelated to other anti-seizure medications and currently is a Schedule I drug. (medpagetoday.com)
  • Here we report that cannabidiol, a major non-psychoactive cannabinoid found in marijuana and its synthetic dimethylheptyl homolog interfere with nausea elicited by lithium chloride and with conditioned nausea elicited by a flavor paired with lithium chloride. (lww.com)
  • Cannabidiol (CBD) is an anti-inflammatory cannabinoid shown to be beneficial in a mouse model of IBD. (springer.com)
  • Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action Canabidiol: de um canabinóide inativo a uma droga com amplo espectro de ação. (springer.com)
  • Cannabidiol is a component of marijuana that does not activate cannabinoid receptors, but moderately inhibits the degradation of the endocannabinoid anandamide. (erowid.org)
  • Cannabidiol, (CBD), is another cannabinoid that acts as an antagonist of the endocannabinoid system. (medscape.com)
  • How is cannabidiol different from marijuana, cannabis and hemp? (harvard.edu)
  • 28, 2022 With the legalization of hemp cultivation, products containing cannabidiol (CBD) have become popular. (sciencedaily.com)
  • CARLSBAD, Calif. , Nov. 4, 2014 /PRNewswire/ -- Hemp Health Inc. , a pioneer in hemp cannabidiol (CBD) products, today launched their line of CBD wellness supplements. (prnewswire.com)
  • Cannabidiol, the main non-psychoactive chemical compound extracted from cannabis and hemp plants, has been approved by FDA for the treatment of a form of epilepsy, and is being investigated for a number of other medical conditions, including, anxiety, pain and inflammation. (asm.org)
  • This crystalline cannabidiol (CBD) is derived from Kentucky-grown hemp and isolated via CO 2 extraction and crystal precipitation. (foodengineeringmag.com)
  • Cannabidiol (CBD) is a phytocannabinoid obtained from the hemp plant (Cannabis sativa). (makingcosmetics.com)
  • Congressional Request for Information regarding the potential for a regulatory pathway for hemp-derived cannabidiol (CBD) products. (cspinet.org)
  • Companion bills in the Senate and House would allow the hemp derivative cannabidiol, also known as CBD, to be used in dietary supplements, foods, and beverages, the bills' four sponsors said on Thursday. (thefern.org)
  • While delta-9-tetrahydrocannabinol (THC) is the major active ingredient, cannabidiol makes up about 40% of cannabis extracts and has been studied for many different uses. (rxlist.com)
  • Cannabidiol might also block some of the psychoactive effects of delta-9-tetrahydrocannabinol (THC). (rxlist.com)
  • Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. (springer.com)
  • Cannabis sativa contains 120 cannabinoids, only two of which have been studied for medical use: delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) 7-9 . (cdc.gov)
  • Cite this: Cannabidiol Found No Better Than Placebo for Hand Arthritis Pain - Medscape - Sep 16, 2021. (medscape.com)
  • In the United States, the FDA has indicated only one brand of prescription cannabidiol called Epidiolex for the treatment of seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, or tuberous sclerosis complex in people one year of age and older. (wikipedia.org)
  • In the European Union, cannabidiol (Epidyolex) is indicated for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome, in conjunction with clobazam, for people two years of age and older. (wikipedia.org)
  • If you suddenly stop taking cannabidiol, you may experience withdrawal symptoms such as new or worsening seizures. (medlineplus.gov)
  • May 28, 2019 A synthetic, non-intoxicating analogue of cannabidiol (CBD) is effective in treating seizures in rats, according to research by chemists. (sciencedaily.com)
  • Cannabidiol is touted as helping with a number of different conditions, such as anxiety, pain, and seizures, and is available in a variety of different formulations including food products, oral tinctures, and topical creams. (pharmacytimes.com)
  • Some early research suggests that taking cannabidiol daily for up to 18 weeks might reduce seizures in some people. (rxlist.com)
  • However, other research shows that taking cannabidiol daily for 6 months does not reduce seizures in people with epilepsy . (rxlist.com)
  • Pharmaceutical-grade cannabidiol (Epidiolex) as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome received positive words from FDA staff in briefing documents issued in advance of an FDA advisory committee meeting that will be held Thursday. (medpagetoday.com)
  • In both LGS studies, patients treated with cannabidiol showed significantly greater reductions in drop seizures -- the primary endpoint -- than placebo groups. (medpagetoday.com)
  • In the Dravet syndrome trial, children who received cannabidiol had significantly greater reductions in the primary endpoint of convulsive seizures than placebo-treated patients. (medpagetoday.com)
  • More patients on cannabidiol had at least a 50% reduction in convulsive seizures compared with those on placebo. (medpagetoday.com)
  • The use of marijuana , and more specifically cannabidiol , in people with seizures is much more broadly researched in adults compared with pediatric patients , although several recent review articles have been published. (bvsalud.org)
  • CBD , or cannabidiol, is the second most prevalent active ingredient in cannabis (marijuana). (harvard.edu)
  • Cannabidiol is a substance isolated from the cannabis plant, which is the same plant from which tetrahydrocannabinol (THC), the psychoactive component of marijuana, is derived. (pharmacytimes.com)
  • Cannabidiol is a chemical in the Cannabis sativa plant, also known as marijuana. (rxlist.com)
  • Cannabidiol (CBD), an important terpenoid compound from marijuana with no psychoactive effects, has become of great pharmaceutical interest for several health conditions. (researchgate.net)
  • The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. (springer.com)
  • This article seeks to provide a pathophysiological basis for cannabidiol in epilepsy , discuss commercially available products and nonpharmaceutical marijuana , and review recent evidence in pediatric epilepsy . (bvsalud.org)
  • As of 2019[update], clinical research on CBD included studies related to anxiety, cognition, movement disorders, and pain, but there is insufficient high-quality evidence that cannabidiol is effective for these conditions. (wikipedia.org)
  • As of 2019[update], there was limited high-quality evidence for cannabidiol having a neurological effect in humans. (wikipedia.org)
  • Also during Friday's meeting, the Medical Cannabidiol Board is expected to consider several recommendations from its 2019 annual report that will be sent to lawmakers prior to the 2020 session of the state legislature. (hightimes.com)
  • If the Medical Cannabidiol Board votes to approve one or more of the petitions to add qualifying conditions to the state's medical cannabis program, they will continue to the Iowa Medical Board for another vote there. (hightimes.com)
  • Iowa's medical cannabidiol program began distributing medical cannabis to certified patients on December 1, 2018. (iowa.gov)
  • You may take cannabidiol either with or without food, but be sure to take it the same way each time. (medlineplus.gov)
  • Take cannabidiol at around the same times every day. (medlineplus.gov)
  • Take cannabidiol exactly as directed. (medlineplus.gov)
  • Continue to take cannabidiol even if you feel well. (medlineplus.gov)
  • Cannabidiol has antipsychotic effects. (rxlist.com)
  • The results suggest that inhibition of anandamide deactivation may contribute to the antipsychotic effects of cannabidiol potentially representing a completely new mechanism in the treatment of schizophrenia. (erowid.org)
  • Cannabidiol (CBD) is a phytocannabinoid discovered in 1940. (wikipedia.org)
  • Dimethylheptyl-cannabidiol (DMH-CBD), a non-psychoactive, synthetic derivative of the phytocannabinoid cannabidiol (CBD), has been reported to be anti-inflammatory in RAW macrophages. (unboundmedicine.com)
  • In the United States, the cannabidiol drug Epidiolex was approved by the Food and Drug Administration (FDA) in 2018 for the treatment of two epilepsy disorders. (wikipedia.org)
  • Cannabidiol (CBD), a non-psychoactive compound in cannabis, is being touted as beneficial for many health conditions, ranging from anxiety to epilepsy. (sciencedaily.com)
  • Cannabidiol is known to interact with multiple epilepsy drugs and has been linked to raised liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT), notably with concomitant valproate (Depakote). (medpagetoday.com)
  • Cannabidiol (CBD), the major nonpsychoactive Cannabis constituent, has been proposed for the treatment of a wide panel of neurological and neuropsychiatric disorders, including anxiety, schizophrenia, epilepsy and drug addiction due to the ability of its versatile scaffold to interact with diverse molecular targets that are not restricted to the endocannabinoid system. (nih.gov)
  • Cannabidiol for the Treatment of Pediatric Epilepsy. (bvsalud.org)
  • The Cannabidiol Use in the Treatment of Epilepsy. (bvsalud.org)
  • Epidiolex/Epidyolex is the first prescription formulation of plant-derived cannabidiol approved by regulatory bodies in the US and Europe. (wikipedia.org)
  • Social media surveillance for perceived therapeutic effects of cannabidiol (CBD) products. (physiciansweekly.com)
  • CBD is the acronym for cannabidiol, one of the active compounds found in the Cannabis sativa plant. (doctorshealthpress.com)
  • C 2 Pharma and Anklam Extrakt announced at CPhI 2018, Madrid their R&D collaboration to develop GMP-compliant manufacture of cannabidiol CBD-based compounds. (manufacturingchemist.com)
  • Some early research shows that taking cannabidiol daily for 4 weeks improves psychotic symptoms in people with Parkinson's disease and psychosis . (rxlist.com)
  • Research on the use of cannabidiol for psychotic symptoms in people with schizophrenia is conflicting. (rxlist.com)
  • Some early research suggests that taking cannabidiol four times daily for 4 weeks improves psychotic symptoms and might be as effective as the antipsychotic medication amisulpride. (rxlist.com)
  • This collaboration supports C 2 Pharma's major initiative to bring a reliable source of naturally extracted GMP-compliant Cannabidiol (CBD) to the pharma industry, also reported by Manufacturing Chemist . (manufacturingchemist.com)
  • According to the U.S. Food and Drug Administration (FDA), because cannabidiol has been studied as a new drug, products containing cannabidiol are not defined as dietary supplements. (rxlist.com)
  • But there are still products labeled as dietary supplements on the market that contain cannabidiol. (rxlist.com)
  • Cannabidiol, or CBD, products are everywhere these days. (doctorshealthpress.com)
  • Pointing to a lack of scientific research, the FDA said on Thursday that it would not consider rulemaking for the use of cannabidiol products as dietary or food supplements or in animal feed. (thefern.org)
  • The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol ("CBD") and Cannabigerol ("CBG") Edibles market segment. (advfn.com)
  • Some countries have eased regulations around cannabidiol, to consider products containing CBD to be medical products. (mauritiustimes.com)
  • It was hoped that comparison of the products formed by smoking cannabidiol (I, CBD) through a water-pipe which is the general way of smoking by heavy cannabis users in the eastern countries, and the products formed by treatment of CBD under several pyrolytic conditions may contribute to reach this goal. (who.int)
  • It is not known exactly how cannabidiol works to prevent seizure activity. (medlineplus.gov)
  • Cannabidiol also produced greater median reduction in seizure frequency and higher overall improvement on the Subject/Caregiver Global Impression of Change (S/CGIC) scale. (medpagetoday.com)
  • Cannabidiol doses of up to 300 mg daily have been taken by mouth safely for up to 6 months. (rxlist.com)
  • More specifically, this clinical trial has been planned as a prospective, double-blind, placebo-controlled study, to examine the: Effects of Different Cannabidiol Doses on Reducing the Frequency and Severity of Nausea in Otherwise Healthy Pregnant Women with Excessive First Trimester Emesis and the Diagnosis of Hyperemesis Gravidarum. (advfn.com)
  • Cannabidiol, a non-psychoactive component of cannabis and it. (lww.com)
  • Cannabidiol (CBD) is a major non-intoxicating component of cannabis and possesses anti-epileptic, anxiolytic and anti-hyperalgesic properties. (researchgate.net)
  • A detailed evaluation of potential drug-induced liver injury accompanied the briefing document, as did a memorandum from the FDA controlled substances staff concluding that cannabidiol has negligible abuse potential. (medpagetoday.com)
  • In fact, the WHO website 'Online Q&A' of December 2017 about cannabidiol (compound of cannabis) notes that 'Its legal status in countries is something for national legislators to decide . (mauritiustimes.com)
  • World Health Organization: Cannabidiol (CBD) Pre-Review Report, Expert Committee on Drug Dependence Thirty-ninth Meeting, Geneva, Switzerland, Nov. 6-10, 2017. (medscape.com)
  • In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. (erowid.org)
  • Preliminary screening of cannabidiol (CBD) revealed that CBD is active against HCV but not against HBV in vitro . (nih.gov)
  • Research on other uses for cannabidiol includes several neurological disorders, but the findings have not been confirmed to establish such uses in clinical practice. (wikipedia.org)
  • Your doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with cannabidiol and each time you refill your prescription. (medlineplus.gov)
  • The conflicting results might be related to the cannabidiol dose used and duration of treatment. (rxlist.com)
  • Cannabidiol (CBD) may be used separately or in conjunction with standard treatment to reduce symptoms of juvenile idiopathic arthritis. (hcplive.com)
  • While cannabidiol (CBD) is currently infrequently used for the treatment of juvenile idiopathic arthritis (JIA), there is a large interest in integrating CBD among the caregivers in this patient population, according to a study published in Pediatric Rheumatology . (hcplive.com)
  • Either treatment was safe and led to significant clinical improvement, but cannabidiol displayed a markedly superior side-effect profile. (erowid.org)
  • Moreover, cannabidiol treatment was accompanied by a significant increase in serum anandamide levels, which was significantly associated with clinical improvement. (erowid.org)
  • While there are various treatment options available, recent research suggests that cannabidiol (CBD) may hold promise in managing diabetes symptoms. (ccdsf.com)
  • Cannabidiol does not appear to have any intoxicating effects such as those caused by ∆9-THC in cannabis, but it is under preliminary research for its possible anti-anxiety and anti-psychotic effects. (wikipedia.org)
  • To assess the effects of cannabidiol on Crohn's disease in a randomized placebo-controlled trial. (springer.com)
  • Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. (springer.com)
  • Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells. (unboundmedicine.com)
  • TY - JOUR T1 - Anti-inflammatory effects of the cannabidiol derivative dimethylheptyl-cannabidiol - studies in BV-2 microglia and encephalitogenic T cells. (unboundmedicine.com)
  • We investigated if nonpsychotropic cannabinoids, such as cannabidiol (CBD), produced similar effects in this experimental model of ACD. (aspetjournals.org)
  • Cannabidiol delivers the side effects patients desire without altering their state of mind or making them feel "high. (marijuanadoctors.com)
  • Early research shows that taking cannabidiol daily does not improve symptoms of Huntington's disease. (rxlist.com)
  • Multiple sclerosis (MS) . There is inconsistent evidence on the effectiveness of cannabidiol for symptoms of multiple sclerosis . (rxlist.com)
  • Cannabidiol is in a class of medications called cannabinoids. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to cannabidiol, any other medications, sesame seed oil, or any of the ingredients in cannabidiol solution. (medlineplus.gov)
  • Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings. (jackherer.com)
  • Cannabidiol (CBD) is highly lipophilic, and its oral bioavailability is known to be very low in humans. (karger.com)
  • The average CDAI before cannabidiol consumption was 337 ± 108 and 308 ± 96 ( p = NS) in the CBD and placebo groups, respectively. (springer.com)
  • Use of cannabidiol (CBD) as an add-on pain management technique in patients with either hand osteoarthritis (OA) or psoriatic arthritis (PsA) did not significantly decrease pain intensity when compared with a placebo in a randomized, double-blind trial described as the first of its kind to investigate the effect of pure CBD as an add-on analgesic therapy in patients with joint disease. (medscape.com)
  • Iowa's Medical Cannabidiol Board will consider changes to the state's limited medicinal cannabis program on Friday, including petitions to add new medical conditions that qualify patients to participate in it. (hightimes.com)
  • We conducted a pilot, randomised double blind placebo controlled study set out to assess the impact of the ad-hoc use of cannabidiol (CBD) in smokers who wished to stop smoking. (jackherer.com)
  • 2 have caused much confusion and uncertainty whether oral cannabidiol (CBD) is safe and whether subjects who are treated with CBD run the risk of positive workplace tests on delta9-tetrahydrocannabinol (delta9-THC, in short THC) with the respective consequences. (genengnews.com)
  • He also stated that 'as of now the World Health Organisation has not recommended cannabidiol for medical use' and that 'the WHO Expert Committee will undertake a comprehensive review of cannabis and cannabis related substances in June 2018. (mauritiustimes.com)
  • The WHO's Expert Committee on Drug Dependence focused on cannabidiol , or CBD, one of the naturally occurring cannabinoids found in cannabis plants. (medscape.com)
  • CBD is cannabidiol, one of the major constituents of cannabis. (drweil.com)
  • Today on PubMed.gov, a medical research database sponsored by the National Center for Biotechnology Information, there are citations for 1,270 academic articles specifically on cannabidiol. (prnewswire.com)
  • CB2: Cannabis receptor 2, CBD: Cannabidiol, DNA: Deoxyribonucleic acid, HBV: Hepatitis B virus, HCV: Hepatitis C virus, HIV/AIDS: Human immunodeficiency virus/acquired immune deficiency syndrome, HSC: Hepatic stellate cells, MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium, PCR: Polymerase chain reaction. (nih.gov)
  • More evidence is needed to rate the effectiveness of cannabidiol for these uses. (rxlist.com)
  • Under extended exposure conditions that lead to resistance against vancomycin or daptomycin, Cannabidiol did not lose effectiveness. (asm.org)
  • In light of this, possible risks associated with cannabidiol appeared acceptable: "Although the risk of liver injury has the potential to be serious, the observed risk can be appropriately managed with inclusion of relevant language in labeling, education of prescribers regarding the risk of transaminase elevation and need for monitoring of liver enzyme levels, and further characterization of the risk in the post-market setting," the document said. (medpagetoday.com)
  • Cannabidiol is POSSIBLY SAFE when taken by mouth or sprayed under the tongue appropriately in adults. (rxlist.com)
  • Early research suggests that taking cannabidiol daily for 6 weeks might improve dystonia by 20% to 50% in some people. (rxlist.com)
  • Early research suggests that taking 160 mg of cannabidiol before bed improves sleep time in people with insomnia. (rxlist.com)
  • Some early research suggests that using a cannabidiol spray under the tongue might improve pain and muscle tightness in people with MS. However, it does not appear to improve muscle spasms, tiredness, bladder control, the ability to move around, or well-being and quality of life . (rxlist.com)
  • However, other early research suggests that taking cannabidiol for 14 days is not beneficial. (rxlist.com)
  • Early research suggests that inhaling cannabidiol with an inhaler for one week might reduce the number of cigarettes smoked by about 40% compared to baseline. (rxlist.com)
  • Some early research shows that taking cannabidiol 300 mg daily does not improve anxiety in people with social anxiety disorder . (rxlist.com)
  • MONTREAL, QC, CANADA - Taking cannabidiol, a chemical in the cannabis sativa plant, appears ineffective in treating cocaine use disorder, researchers at the CHUM Research Centre find. (labmanager.com)